Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)
of the IXORA-P Investigators
科研成果: 期刊稿件 › 文章 › 同行评审
46
引用
（Scopus）